These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 22097686)
1. Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre experience. Vondráková D; Málek F; Dvorák J; Sedivá L; Kupec J; Petrů J; Táborský M; Neuzil P Vnitr Lek; 2011 Oct; 57(10):799-802. PubMed ID: 22097686 [TBL] [Abstract][Full Text] [Related]
2. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014 [TBL] [Abstract][Full Text] [Related]
3. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483 [TBL] [Abstract][Full Text] [Related]
4. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ; Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773 [TBL] [Abstract][Full Text] [Related]
5. Cardiac resynchronization therapy allows the optimization of medical treatment in heart failure patients. Kachboura S; Ben Halima A; Ibn Elhadj Z; Marrakchi S; Chrigui R; Kammoun I; Chine S; Lefi A Ann Cardiol Angeiol (Paris); 2014 Feb; 63(1):17-22. PubMed ID: 23932251 [TBL] [Abstract][Full Text] [Related]
6. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Schmidt S; Hürlimann D; Starck CT; Hindricks G; Lüscher TF; Ruschitzka F; Steffel J Eur Heart J; 2014 Apr; 35(16):1051-60. PubMed ID: 24371079 [TBL] [Abstract][Full Text] [Related]
7. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic]. Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474 [TBL] [Abstract][Full Text] [Related]
8. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842 [TBL] [Abstract][Full Text] [Related]
9. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849 [TBL] [Abstract][Full Text] [Related]
10. Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Nielsen JC Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):182-8. PubMed ID: 27533993 [TBL] [Abstract][Full Text] [Related]
11. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
12. Adjustments of heart failure medication after implantation of a cardiac resynchronization therapy defibrillator. Hitz L; Kühne MS; Sticherling C; Osswald S; Schaer BA Minerva Med; 2012 Oct; 103(5):361-7. PubMed ID: 23042371 [TBL] [Abstract][Full Text] [Related]
13. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis. Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318 [TBL] [Abstract][Full Text] [Related]
14. [Beta blockers and ACE inhibitors In heart failure to be combined at the beginning!]. MMW Fortschr Med; 2002 Nov; 144(45):58. PubMed ID: 12534067 [No Abstract] [Full Text] [Related]
15. Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Hauptman PJ; Swindle JP; Masoudi FA; Burroughs TE Circ Cardiovasc Qual Outcomes; 2010 Mar; 3(2):204-11. PubMed ID: 20197509 [TBL] [Abstract][Full Text] [Related]
16. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients]. Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025 [TBL] [Abstract][Full Text] [Related]